Acta Psychiatrica Scandinavica
September 8, 2023
Giacomo D’andrea, Mauro Pettorruso, T. Rhee et al.
8 citations
Depressive disorders represent a significant economic and health burden globally. This is particularly evident in treatment-resistant depression (TRD), commonly defined as the absence of a satisfactory response to at least two different antidepressant trials (as defined by the U.S. Food and Drug Administration/FDA and European Medicine Agencies/EMA). The foregoing TRD cases frequently manifest...
BMC Complementary Medicine and Therapies
September 8, 2023
Chuyuan Miao, Yun Gao, Xiaohua Li et al.
19 citations
Mindfulness yoga is a type of exercise that emphasizes the integration of mindfulness or meditation into yoga. The aim of this study was to determine the effectiveness of mindfulness yoga intervention on major depressive disorder (MDD) patients. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted by searching nine databases, including PubMed, EMBASE, Web...
Clinical Psychopharmacology and Neuroscience
September 6, 2023
Julia Vendrell-Serres, Oscar Soto-Angona, Amanda Rodríguez‐Urrutia et al.
8 citations
Objective: : Treatment Resistant Depression (TRD) is commonly defined as the lack of response to two or more anti-depressants with different mechanisms of action. Up to 30% of patients diagnosed with major depressive disorder might be considered to present TRD. The objective of this study was to assess the effectiveness and tolerability of esketamine in patients diagnosed with TRD, who were...
Psychedelic Medicine
September 6, 2023
Marc J. Weintraub, Jessica K Jeffrey, Charles S. Grob et al.
4 citations
The trial will provide preliminary data on the feasibility, safety, acceptability, and psychosocial effects of PA-CBT. Results will inform randomized clinical trials to test the effects of PA-CBT for patients with depression and other mental health conditions, as well as hypotheses concerning mediating mechanisms at the cognitive and affective levels. ClinicalTrials.gov ID: NCT05227612.
Media Ilmu Kesehatan
September 1, 2023
Nanik Lestari, Ferry Efendi, Nuzul Qur'aniati et al.
Background: Globally, there is an increase in mental health issues. The prevalence of mental health issues among 10 to 19-year-olds is estimated to be 1 in 7 (14%) globally, despite the fact that most of these conditions go undiagnosed and untreated. Mindfulness techniques have been employed consistently, and has suggested associated criteria for the treatment of depression. Objective: This...
Journal of Clinical Psychopharmacology
September 1, 2023
Philip R Wang, Mani Yavi, Holim Lee et al.
Abstract: Background: Approximately one third of individuals with major depressive disorder have treatment-resistant depression (TRD). Glutamatergic modulators such as the N-methyl-d-aspartate receptor antagonist ketamine have rapid and robust antidepressant effects, but their use has been limited by accessibility and route of administration. This open-label pilot study assessed the adjunctive...
The Brown University Psychopharmacology Update
September 1, 2023
Interim results from a Phase 3 study of esketamine nasal spray in patients with treatment‐resistant depression showed no emerging safety concerns and sustained improvement in depressive symptoms. Nearly half of study participants met criteria for remission at the end of the study's optimization/maintenance phase, the investigators reported. Study results were published online May 12, 2023, in...
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
September 2023
Chan Li, Jiping Zhang, Hanhe Liu et al.
Depression is a multifactorial syndrome with a variety of underlying pathological mechanisms. While ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, exhibits a rapid antidepressant action in the central never system (CNS), the potential addiction and psychotomimetic adverse effects of ketamine limit its chronic use in clinical practice. Therefore, it is necessary to discover an...
The Brown University Psychopharmacology Update
September 1, 2023
A large‐scale open‐label trial conducted at electroconvulsive therapy (ECT) clinics has found that twice‐weekly dosing of ketamine was noninferior to three sessions a week of ECT in patients with treatment‐resistant major depression. Relapse rates during a 6‐month follow‐up period after the initial 3‐week treatment period were higher among patients receiving ECT than patients receiving...
International Clinical Psychopharmacology
September 1, 2023
Nicolas Garel, Michka Nazon, Kamran Naghi et al.
7 citations
Medical Aid in Dying (MAiD) is the act of a healthcare provider ending a patient's life, at their request, due to unbearable suffering from a grievous and incurable disease. Access to MAiD has expanded in the last decade and, more recently, it has been made available for psychiatric illnesses in a few countries. Recent studies have found that such psychiatric requests are rapidly increasing and...